ライフサイエンスコーパス: galantamine

1 inesterase inhibitors, such as donepezil and galantamine.

2 different modes of action for donepezil and galantamine.

3 ent in patients receiving 16 or 24 mg/day of galantamine.

4 nicotine-evoked responses occurred at 1 muM galantamine.

5 erminant of the therapeutic effectiveness of galantamine.

6 bed dosage ranges, donepezil (1-1000 nM) and galantamine (50-1000 nM) increase action potential-depen

7 ase who were randomly assigned to placebo or galantamine (8, 16, or 24 mg/day) were analyzed.

8 chnique was used to determine the effects of galantamine, a cholinesterase inhibitor and a nicotinic

9 Galantamine, a cholinesterase inhibitor used in Alzheime

10 alysis was conducted to assess the impact of galantamine, a cholinesterase inhibitor with nicotinic-r

11 Here, we demonstrate that galantamine, a reversible and centrally acting AChE inhi

12 and human cerebral cortical slices, 1 microM galantamine, acting as a nicotinic APL, increased gamma-

13 Likewise, 1 microM galantamine, acting as an APL on presynaptically located

14 We conclude that galantamine activates the muscle-type ACh receptor by in

15 combination with atropine, a single dose of galantamine administered before or soon after acute expo

16 Acute galantamine administration (5.0 mg/kg, i.p.) attenuated

17 Galantamine administration also attenuated the reinstate

18 ever, there are no studies examining whether galantamine administration modulates nicotine self-admin

19 ts were designed to determine the effects of galantamine administration on nicotine taking and reinst

20 signed to examine the efficacy and safety of galantamine, an acetylcholinesterase inhibitor that also

21 183 of 207 patients (88%) who received galantamine and 177 of 200 (89%) who received placebo ha

22 Forty-two subjects were assigned to galantamine and 44 were assigned to placebo.

23 The combined cerebral metabolic effects of galantamine and citalopram suggest, consistent with prec

24 ved) by 1.9 (95% CI -0.1 to 3.9) points with galantamine and decreased (worsened) by 3.0 (-5.6 to -0.

25 Ki values of brain AChE inhibition for galantamine and donepezil, respectively, are 7.1 and 2.3

26 The brain-to-plasma ratio for galantamine and donepezil, respectively, ranges from 1.2

27 geted compounds obtained by linking together galantamine and memantine.

28 ad similar effects on receptor activation by galantamine and nicotinic agonists, suggesting that the

29 d previously for the nonselective nAChR PAMs galantamine and physostigmine at the canonical alpha-gam

30 ts performed in the simultaneous presence of galantamine and various nicotinic ligands showed that ch

31 e general features of receptor activation by galantamine are similar to that in the presence of ACh.

32 choline) was not affected by the presence of galantamine at concentrations up to 100 microm.

33 Thus, a galantamine-based therapy emerges as an effective and sa

34 r, there is also evidence demonstrating that galantamine can activate the nicotinic ACh receptor or m

35 Galantamine can be started and used safely in elderly pa

36 erlie the allocation of attention or whether galantamine changed the mapping from those beliefs to su

37 Studies of direct activation by galantamine demonstrated that this ligand is a low-effic

38 acetylcholinesterase (AChE) in complex with galantamine derivatives.

39 Galantamine did not compete for radioligand binding to t

40 In addition, galantamine did not reduce the initial rate of binding f

41 These results demonstrate that galantamine does not interfere with the occupation of th

42 patients 2 months after titration to a 24 mg galantamine dose.

43 Galantamine doses between 1.5 and 5 mg/kg are appropriat

44 p analyses revealed that the subjects taking galantamine exhibited significant improvements on the WA

45 The efficacy of galantamine for cognitive impairments was evaluated with

46 Clearance of galantamine from the brain is in general faster that don

47 The allosterically potentiating ligand galantamine (Gal) modulates nicotinic cholinergic recept

48 168 of 207 (81%) patients in the galantamine group and 161 of 200 (81%) in the placebo gr

49 Eight patients (4%) in the galantamine group and 21 patients (11%) in the placebo g

50 eas patients treated with 16 or 24 mg/day of galantamine had no change in total Neuropsychiatric Inve

51 tiation was blocked by mecamylamine, whereas galantamine had no effect on these measures in the absen

52 The efficacy of galantamine has been shown in patients with mild, modera

53 Galantamine has recently been shown to reverse nicotine

54 Trials of galantamine, hydrocortisone, IgG, valganciclovir, isopri

55 Galantamine improved cognitive function but failed to si

56 onepezil is 40- to 500-fold more potent than galantamine in inhibiting AChE.

57 values for AChE inhibition for donepezil and galantamine in rat, mouse, and rabbit after subcutaneous

58 Galantamine is a rather weak acetylcholinesterase (AChE)

59 Galantamine is an acetylcholinesterase inhibitor that al

60 Galantamine is known to sensitize nAChRs to activation b

61 Therefore, at 1 microM, galantamine is likely to increase facilitation of synapt

62 Behaviorally, galantamine led to a greater influence of probabilistic

63 ive impairments in mice, which suggests that galantamine may function to prevent relapse in human smo

64 Study results suggest that galantamine may have selective benefits for aspects of p

65 maries provide some evidence of benefits for galantamine, modafinil, levodopa, rotigotine, clozapine,

66 me setting were randomly assigned to receive galantamine (n=207), titrated initially to 24 mg/day, or

67 Doses of galantamine needed to protect guinea pigs fully against

68 icant between-group differences in favour of galantamine occurred for the SIB domains of memory (p=0.

69 nicotine self-administration, no effects of galantamine on nausea/malaise as measured by pica were n

70 No significant effects of galantamine on sucrose self-administration or sucrose re

71 Moreover, the effects of galantamine on sucrose-maintained responding and sucrose

72 inhibitor and nicotinic receptor modulator, galantamine, on the cerebral metabolic response to the s

73 Three donepezil, two galantamine, one rivastigmine, and two memantine trials,

74 We administered tacrine, galantamine or memantine to mouse cerebral cortical cult

75 In SH-SY5Y cells, galantamine potentiated nicotine-evoked increases in int

76 irenz (EFV), acetaminophen, mirtazapine, and galantamine) prescribed for indications unrelated to cho

77 challenge with the cholinesterase inhibitor galantamine (Reminyl).

78 Galantamine (Reminyl; Janssen Pharmaceutica, Titusville,

79 lcholinesterase inhibitor and Alzheimer drug galantamine represents the prototypical allosteric ligan

80 king were also examined to determine whether galantamine's effects generalized to other reinforced be

81 of brain AChE inhibition, 3-15 times higher galantamine than donepezil doses are needed.

82 Unlike galantamine, the acetylcholinesterase inhibitors rivasti

83 Galantamine therapy was associated with reduced emergenc

84 this study, we have examined the ability of galantamine to directly activate the muscle-type nicotin

85 ork was to enhance the transportation of the galantamine to the brain via ascorbic acid grafted PLGA-

86 acebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints

87 Galantamine treatment alone increased metabolism in the

88 In contrast, during galantamine treatment, citalopram increased metabolism i

89 High-dose galantamine was associated with a significant reduction

90 In preventing the lethality of nerve agents, galantamine was far more effective than pyridostigmine,

91 In general, safety analyses revealed that galantamine was well tolerated.

92 In addition, galantamine, which is both an inhibitor of AChE and an a

93 m hippocampal slices was also potentiated by galantamine, with an additional component attributable t